Longeveron LGVN 深 滬
已收盤 06-18 16:00:00 美东时间
0.8201
-0.020
-2.37%
華盛通- 最 高0.865
- 今 開0.84
- 成交量 24.09万股
- 最 低 0.8157
- 昨 收 0.84
- 總市值 2591.35万
- 52周最高 1.80
- 市盈率 靜 --
- 換手率 0.76%
- 52周最低 0.475
- 委 比 -81.18%
- 總股本 3159.80万
- 歷史最高 450.00
- 量 比 1.31
- 振 幅 5.87%
- 歷史最低 0.475
- 每 手 1
- 風險率 0.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Longeveron Granted Small Or Medium-Sized Enterprise Status By European Medicines Agency
According to the EMA, SME Designation has allowed for improved success rate for organizations seeking regulatory approvals:the success rate for SME marketing authorization applications for human medicines more than
06-09 21:21
Longeveron CFO Lisa Locklear Plans To Step Down, Effective July 10
https://www.sec.gov/ix?doc=/Archives/edgar/data/1721484/000121390026065788/ea0293758-8k_longeveron.htm
06-06 04:04
Longeveron to Present at BIO International Convention 2026
Longeveron Inc. will participate in the BIO International Convention 2026 to present its stem cell therapy laromestrocel, focusing on potential partnerships for Hypoplastic Left Heart Syndrome, Alzheimer’s disease, Pediatric Dilated Cardiomyopathy, and Aging-related Frailty. The company aims to leverage strategic collaborations to accelerate development and commercialization, with laromestrocel showing positive results across multiple clinical tr...
06-04 13:15
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
Longeveron Inc. CEO Stephen Willard outlines the company's strategic repositioning to maximize stockholder value and focuses on its stem cell therapy, laromestrocel, for life-threatening conditions. Key priorities include advancing the Phase 2b HLHS trial with expected data in August 2026, expanding into PDCM, and pursuing partnerships for Alzheimer’s disease and aging-related frailty. The company has secured new investments and aims to leverage ...
05-20 20:05
电话会总结 ｜ Longeveron(LGVN)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Longeveron业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2026年第一季度总营收40万美元，与2025年同期持平。其中临床试验收入40万美元，合同制造收入2万美元。 **亏损情况：** 净亏损470万美元，较2025年同期的500万美元减少30万美元。 **费用控制：** 一般管理费用270万美元，研发费用230万美元，两项费用均实现同比下降。 **现金状况：** 截至2026年3月31日，现金及现金等价物余额1,580万美元。 ## 2. 财务指标变化 **营收结构变化：** - 临床试验收入同比增长
05-14 12:24
Longeveron Q1 2026 Earnings Call: Complete Transcript
On Wednesday, Longeveron (NASDAQ:LGVN) discussed first-quarter financial result...
05-14 05:09
Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate
Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 44.12 percent increase over losses of $(0.34) per share from the
05-14 04:42
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Maxim Group Downgrades Longeveron to Hold
Maxim Group analyst Michael Okunewitch downgrades Longeveron (NASDAQ:LGVN) from Buy to Hold.
05-12 03:42
Longeveron Phase 2b HLHS Cell Therapy Trial Clears Final Safety Review; Top-Line Results Expected August 2026
Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationDMC performed a risk-benefit assessment, identified no new
05-11 21:11
